Latest News

May 23, 2024
CE Approval for Medinol’s EluNIR-PERL™ Drug-Eluting Stent System

We are thrilled to announce that our innovative EluNIR-PERL™ DES has received CE approval! This marks a significant milestone in our commitment to advancing cardiovascular care and offering pioneering solutions to patients worldwide.

Read More
May 20, 2024
Dr. Raj Dave of Cardiovascular Experts of PA implanted the EluNIR - PERL DES

Dr. Dave noted, “The platinum marker on EluNIR – PERL allows accurate and precise placement in the most challenging coronary anatomy.”

A big thanks to the team at Cardiovascular Experts of PA and CoSo Health for helping patients and saving lives through innovative technology.

CoSo Health partners with Medinol to bring Elunir – PERL to hospitals and ASCs throughout the U.S. and Brazil.

Read More
April 25, 2024
FDA Approves Early Feasibility Study for our Groundbreaking ChampioNIR™ Drug-Eluting Peripheral Stent System

This is a significant milestone in our mission to bring advanced solutions for treating peripheral artery disease.

The EFS will allow us to evaluate the safety and performance of this novel stent technology in a clinical setting. We’re grateful for this opportunity to further our research and development efforts.

Read More
October 24, 2023
Medinol Receives FDA Approval for Next Generation EluNIR-PERL™ Drug-Eluting Coronary Stent System

Medinol today announced United States Food and Drug Administration (FDA) approval for the EluNIR-PERL™ drug-eluting stent (DES) for the treatment of coronary artery disease.

Read More
August 18, 2023
Clinical considerations during spontaneous coronary artery dissection in the post-partum period: a case report

Emotional Case Report that was published in the European Society of Cardiology, European Heart Journal on 18 August 2023: “Clinical considerations during spontaneous coronary artery dissection in the post-partum period: a case report.”

Read More
June 8, 2023
TVT Conference - Valve Medical, First-in-Human TAVI Implant

Prof Eberhard Grube presented the successful FIH implantation of the XEMED TAVR device at the TVT 2023 Structural Heart Summit.


Read More
May 31, 2023
Valve Medical Announces Successful First-in-Human Implantation of Ultra-low Profile TAVR Valve in Israel

Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel.

Read More
May 31, 2023
CTO Live Cases

We were proud to participate with our EluNIR DES System in the CTO Live Cases from 9 international centers with 26 expert interventional cardiologists on May 31st, 2023.

Read More
May 29, 2023
UP NEXT summit, Sourasky Medical

 Dr. Yoram Richter Medinol’s CEO joined a session on “Innovative stents and valves in cardiac disease” at the UP NEXT summit, Sourasky Medical Center (Ichilov), The first Israeli conference for technological innovation in healthcare.

Read More
May 25, 2023
Pavlodar City Cardio Center Conference

Our EluNIR DES System was presented last week at the Pavlodar City Cardio Center Conference, Kazakhstan, by our respected local distributor Dan Med LLP.

Read More
May 18, 2023
Medinol - PCR 2023

On PCR 2023, Prof. Maayan Konigstein, Director Interventional Cardiology Catheterization Unit, Tel Aviv Sourasky Medical Center – Ichilov in a lecture on: “The Medinol IoNir hybrid coronary DES system”.

Read More
May 5, 2020
Medinol Completes Enrollment of EluNIR-HBR Study

Medinol announces completion of enrollment in its EluNIR HIGH BLEEDING RISK (HBR) trial. A prospective, multi-center, single-arm, open-label post marketing clinical trial, to assess the safety and efficacy of the EluNIR Drug Eluting Stent (DES) in combination with shortened DAPT duration, in patients undergoing PCI who are considered to be at high bleeding risk.

Read More

Accessibility Toolbar